High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis.
Rheumatoid arthritis (RA) remains a prevalent disease worldwide that causes significant morbidity and mortality despite recent therapeutics. High mobility group box-1 (HMGB1) protein, originally appreciated as an intranuclear DNA binding protein, has been implicated as an integral mediator in the pathogenesis of animal arthritides and RA disease in humans. Our current understanding of HMGB1 has promoted the development of targeting therapies that have improved outcomes in animal models of inflammation. In the previous issue of Arthritis Research & Therapy, Sundberg and colleagues address, for the first time in a prospective cohort study, whether HMGB1 expression is dependent upon tumor necrosis factor activity in patients with RA.
Richard S
RS
Goldstein
D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000378:metabolism* / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D024243:HMGB1 Protein / Q000378:metabolism*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*
D018501:Antirheumatic Agents; D024243:HMGB1 Protein; D014409:Tumor Necrosis Factor-alpha